Pavilion Capital and Hansjörg Wyss featured in a series B round for Harvard-founded ReadCoor, whose existing shareholders also include Lilly Asia Ventures.
ReadCoor, a US-based gene sequencing spinout of Harvard University, obtained $27m on Friday in a series B round featuring Singaporean government-owned investment vehicle Pavilion Capital.
Investment firm Decheng Capital also participated, as did private investor Hansjörg Wyss, founder of Harvard’s Wyss Institute for Biologically Inspired Engineering, and unnamed existing investors.
Founded in 2016, ReadCoor supplies molecular sequencing products that apply fluorescence to mark out molecular targets before plotting them as coordinates on a 3D image of the sample.
The product, dubbed Fisseq, can sequence both RNA and DNA and is primarily pitched toward medical research in areas such as oncology, infectious disease and neuroscience.
Fisseq advances Harvard University and Wyss Institute research conducted in the lab of George Church, professor of genetics. ReadCoor will use the funding to further its commercialisation strategy.
Hansjörg Wyss joined Lilly Asia Ventures, a corporate venturing arm of drug maker Eli Lilly, for the spinout’s $23m series A round in 2016, investing alongside both Decheng Capital, which led the round, and Vivo Capital.
